Press Releases
- Overview
- Stock Information
- News & Events
- Financials
- Analyst Coverage
- Corporate Governance
- Shareholder Services
-
May 10, 2017- VK5211 Phase 2 hip fracture study enrollment nearing completion
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced...
-
May 3, 2017Conference Call Scheduled for Wednesday, May 10 at 4:30p.m. Eastern Time
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today...
-
Mar 28, 2017
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced...
-
Mar 21, 2017- VK5211 Phase 2 study in hip fracture proceeding, with results expected mid-year
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced...
-
Mar 2, 2017Conference Call Scheduled for Tuesday, March 21st at 4:30p.m. Eastern Time
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today...